Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Entero Healthcare Solutions / Equity Bottom-Up

<ul>
<li>Management expects FY27 MedTech revenue to cross INR 1,000 crore and says Q1 performance is comfortably tracking above that threshold.</li>
<li>MedTech is largely demand generation, not only fulfilment, giving Entero a structurally better opportunity to earn higher gross and EBITDA margins.</li>
<li>Mix shift can lift group margins even if core pharma remains competitive, creating earnings growth faster than revenue and a potential re-rating catalyst.</li>
</ul>


Management expects FY27 MedTech revenue to cross INR 1,000 crore and says Q1 performance is comfortably tracking above that threshold.
MedTech is largely demand generation, not only fulfilment, giving Entero a structurally better opportunity to earn higher gross and EBITDA margins.
Mix shift can lift group margins even if core pharma remains competitive, creating earnings growth faster than revenue and a potential re-rating catalyst.


Entero Healthcare: The Hidden MedTech Opportunity

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Entero Healthcare Solutions / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/entero-healthcare-solutions-limited" target="_blank" data-smartkarma-citation="entities:40156:1" rel="noopener">Entero Healthcare Solutions Limited (2294842D IN)</a> is looking to raise US$200m in its upcoming India IPO. The IPO will consist of both a primary and secondary component.</li>
<li>Entero Healthcare Solutions (Entero) is a healthcare products distributor in India.</li>
<li>In this note, we look at the company’s past performance.</li>
</ul>



Entero Healthcare Solutions Limited (2294842D IN) is looking to raise US$200m in its upcoming India IPO. The IPO will consist of both a primary and secondary component.
Entero Healthcare Solutions (Entero) is a healthcare products distributor in India.
In this note, we look at the company’s past performance.


Entero Healthcare Pre-IPO - Has Been Scaling up Rapidly Aided by a Flurry of Acquisitions

<ul>
<li>Entero Healthcare delivered on all three FY26 guidance parameters simultaneously ,reporting 31.5% LFL revenue growth, 4.0% EBITDA margin, INR 96 crore positive operating cash flow, first full-year OCF positive print.</li>
<li>The transition from cash-consuming acquisition machine to a self-funding growth platform is the key de-risking event, arriving just as the MedTech segment crosses the INR 1,000 crore annualized revenue threshold.</li>
<li>With FY27 guidance targeting 5% EBITDA margins and a 50% OCF-to-EBITDA conversion, Entero's unit economics are compounding faster than the market appears to appreciate.</li>
</ul>


Entero Healthcare delivered on all three FY26 guidance parameters simultaneously ,reporting 31.5% LFL revenue growth, 4.0% EBITDA margin, INR 96 crore positive operating cash flow, first full-year OCF positive print.
The transition from cash-consuming acquisition machine to a self-funding growth platform is the key de-risking event, arriving just as the MedTech segment crosses the INR 1,000 crore annualized revenue threshold.
With FY27 guidance targeting 5% EBITDA margins and a 50% OCF-to-EBITDA conversion, Entero's unit economics are compounding faster than the market appears to appreciate.


Entero Healthcare: Consolidating India’s Fragmented Healthcare Supply Chain

<ul>
<li>Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of <strong>INR 3.3 Trillions.</strong>
</li>
<li>Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross <strong>INR 1,000 crore</strong> on an annualized basis.</li>
<li>Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. </li>
</ul>


Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of INR 3.3 Trillions.

Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross INR 1,000 crore on an annualized basis.
Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. 


Entero Healthcare: New Titan of Pharma Distribution

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Thematic (Sector/Industry)

<ul>
<li>With Nifty 50 earnings growth barely 3% YoY in CY25, companies that voluntarily offer specific, multi-metric guidance signal not just confidence, but accountability. </li>
<li>Management-Backed targets are a meaningful filter in a market where execution risk dominates.</li>
<li>Twenty Indian mid and small-cap companies have issued explicit quantitative growth guidance for FY26–FY27, spanning revenue, EBITDA, and AUM metrics across sectors from specialty chemicals to power systems to CRDMO.</li>
</ul>


With Nifty 50 earnings growth barely 3% YoY in CY25, companies that voluntarily offer specific, multi-metric guidance signal not just confidence, but accountability. 
Management-Backed targets are a meaningful filter in a market where execution risk dominates.
Twenty Indian mid and small-cap companies have issued explicit quantitative growth guidance for FY26–FY27, spanning revenue, EBITDA, and AUM metrics across sectors from specialty chemicals to power systems to CRDMO.


India's Guided Growth Playbook: 20 Companies Telling You Exactly Where They're Going

India

Entero Healthcare Solutions Limited is a large-scale distributor of healthcare products in India, providing an integrated platform for demand generation and fulfillment. The company distributes pharmaceuticals, medical devices, surgical consumables, nutraceuticals, and over-the-counter products to retail pharmacies and hospitals. Entero Healthcare Solutions was founded in 2018 and is headquartered in Mumbai, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Entero Healthcare Solutions (ENTERO IN)

Entero Healthcare: The Hidden MedTech Opportunity

The market sees a pharma distributor. The emerging reality is hybrid healthcare-platform in which a higher-value MedTech engine is beginning to...

Nimish Maheshwari

Entero Healthcare Pre-IPO - Has Been Scaling up Rapidly Aided by a Flurry of Acquisitions

Entero Healthcare Solutions Limited (2294842D IN) is looking to raise US$200m in its upcoming India IPO. The IPO will consist of both a primary and...

Clarence Chu

Entero Healthcare: Consolidating India’s Fragmented Healthcare Supply Chain

Entero Healthcare exceeds FY26 guidance, transitions to self-funding growth platform with strong unit economics for FY27.

Nimish Maheshwari

Entero Healthcare: New Titan of Pharma Distribution

Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...

Nimish Maheshwari

India's Guided Growth Playbook: 20 Companies Telling You Exactly Where They're Going

These are 20 Indian Companies offering specific, multi-metric guidance signal confidence and accountability in a market dominated by execution risk.

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Entero Healthcare: The Hidden MedTech Opportunity

The market sees a pharma distributor. The emerging reality is hybrid healthcare-platform in which a higher-value MedTech engine is beginning to...

Nimish Maheshwari

Entero Healthcare Pre-IPO - Has Been Scaling up Rapidly Aided by a Flurry of Acquisitions

Entero Healthcare Solutions Limited (2294842D IN) is looking to raise US$200m in its upcoming India IPO. The IPO will consist of both a primary and...

Clarence Chu

Entero Healthcare: Consolidating India’s Fragmented Healthcare Supply Chain

​Entero Healthcare exceeds FY26 guidance, transitions to self-funding growth platform with strong unit economics for FY27.

Nimish Maheshwari

Entero Healthcare: New Titan of Pharma Distribution

​Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...

Nimish Maheshwari

India's Guided Growth Playbook: 20 Companies Telling You Exactly Where They're Going

​These are 20 Indian Companies offering specific, multi-metric guidance signal confidence and accountability in a market dominated by execution risk.

Sudarshan Bhandari

Entero Healthcare exceeds FY26 guidance, transitions to self-funding growth platform with strong unit economics for FY27.

Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...

These are 20 Indian Companies offering specific, multi-metric guidance signal confidence and accountability in a market dominated by execution risk.